Marco Roffi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3856553/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal, 2018, 39, 119-177.	2.2	7,100
2	2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal, 2016, 37, 267-315.	2.2	5,890
3	2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal, 2021, 42, 373-498.	2.2	5,583
4	2014 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal, 2014, 35, 2541-2619.	2.2	4,141
5	2014 ESC Guidelines on the diagnosis and treatment of aortic diseases. European Heart Journal, 2014, 35, 2873-2926.	2.2	3,549
6	2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal, 2021, 42, 1289-1367.	2.2	3,048
7	2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). European Heart Journal, 2018, 39, 763-816.	2.2	2,305
8	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. European Heart Journal, 2018, 39, 213-260.	2.2	2,246
9	ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries * The Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC), European Heart Journal, 2011, 32, 2851-2906.	2.2	1,394
10	ESC working group position paper on myocardial infarction with non-obstructive coronary arteries. European Heart Journal, 2017, 38, ehw149.	2.2	511
11	Platelet Glycoprotein IIb/IIIa Inhibitors Reduce Mortality in Diabetic Patients With Non–ST-Segment-Elevation Acute Coronary Syndromes. Circulation, 2001, 104, 2767-2771.	1.6	411
12	Effect of Biolimus-Eluting Stents With Biodegradable Polymer vs Bare-Metal Stents on Cardiovascular Events Among Patients With Acute Myocardial Infarction. JAMA - Journal of the American Medical Association, 2012, 308, 777.	7.4	278
13	Zotarolimus-Eluting Versus Bare-Metal Stents in Uncertain Drug-Eluting Stent Candidates. Journal of the American College of Cardiology, 2015, 65, 805-815.	2.8	248
14	Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk. New England Journal of Medicine, 2021, 385, 1643-1655.	27.0	247
15	Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial. Lancet, The, 2014, 384, 2111-2122.	13.7	224
16	Lack of Benefit From Intravenous Platelet Glycoprotein IIb/IIIa Receptor Inhibition as Adjunctive Treatment for Percutaneous Interventions of Aortocoronary Bypass Grafts. Circulation, 2002, 106, 3063-3067.	1.6	201
17	Effect of high-intensity statin therapy on atherosclerosis in non-infarct-related coronary arteries (IBIS-4): a serial intravascular ultrasonography study. European Heart Journal, 2015, 36, 490-500.	2.2	168
18	Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial. Lancet, The, 2019, 394, 1243-1253.	13.7	138

Marco Roffi

#	Article	IF	CITATIONS
19	Is Bare-Metal Stent Implantation StillÂJustifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?. JACC: Cardiovascular Interventions, 2016, 9, 426-436.	2.9	135
20	EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic. European Heart Journal, 2020, 41, 1839-1851.	2.2	106
21	Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial. Lancet, The, 2018, 392, 737-746.	13.7	101
22	Impact of Different Platelet Glycoprotein IIb/IIIa Receptor Inhibitors Among Diabetic Patients Undergoing Percutaneous Coronary Intervention. Circulation, 2002, 105, 2730-2736.	1.6	87
23	Current concepts on coronary revascularization in diabetic patients. European Heart Journal, 2011, 32, 2748-2757.	2.2	82
24	Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes. European Heart Journal, 2004, 25, 190-198.	2.2	79
25	Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombosis, and the ESC working group on cardiovascular pharmacotherapy. European Heart Journal, 2021, 42, 4013-4024.	2.2	76
26	The Obstacle Course of Reperfusion for ST-Segment–Elevation Myocardial Infarction in the COVID-19 Pandemic. Circulation, 2020, 141, 1951-1953.	1.6	73
27	Procedural Results and Clinical Outcomes of Transcatheter Aortic Valve Implantation in Switzerland. Circulation: Cardiovascular Interventions, 2015, 8, .	3.9	64
28	Carotid artery stenting versus surgery: adequate comparisons?. Lancet Neurology, The, 2010, 9, 339-341.	10.2	63
29	Infective Endocarditis After Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2020, 75, 3020-3030.	2.8	60
30	Carotid artery stenting vs. endarterectomy. European Heart Journal, 2009, 30, 2693-2704.	2.2	58
31	Biolimus-Eluting Stents With Biodegradable Polymer Versus Bare-Metal Stents in Acute Myocardial Infarction. Circulation: Cardiovascular Interventions, 2014, 7, 355-364.	3.9	56
32	Design and rationale of the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen (MASTER DAPT) Study. American Heart Journal, 2019, 209, 97-105.	2.7	53
33	Ultrathin Strut Biodegradable Polymer Sirolimusâ€Eluting Stent Versus Durableâ€Polymer Everolimusâ€Eluting Stent for Percutaneous Coronary Revascularization: 2â€Year Results of the BIOSCIENCE Trial. Journal of the American Heart Association, 2016, 5, e003255.	3.7	50
34	Early exercise after coronary stenting is safe. Journal of the American College of Cardiology, 2003, 42, 1569-1573.	2.8	45
35	Carotid artery stenting: an update. European Heart Journal, 2015, 36, 13-21.	2.2	43
36	Abbreviated Antiplatelet Therapy in Patients at High Bleeding Risk With or Without Oral Anticoagulant Therapy After Coronary Stenting: An Open-Label, Randomized, Controlled Trial. Circulation, 2021, 144, 1196-1211.	1.6	41

#	Article	IF	CITATIONS
37	Flow Impairment During Protected Carotid Artery Stenting: Impact of Filter Device Design . Journal of Endovascular Therapy, 2008, 15, 103-109.	1.5	38
38	Carotid Stenting. Circulation, 2006, 114, e1-4.	1.6	36
39	Impact of the COVID-19 pandemic on interventional cardiology practice: results of the EAPCI survey. EuroIntervention, 2020, 16, 247-250.	3.2	36
40	Biodegradable- Versus Durable-Polymer Drug-Eluting Stents for STEMI. JACC: Cardiovascular Interventions, 2021, 14, 639-648.	2.9	33
41	Predicting Mortality After Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2017, 10, .	3.9	32
42	The hospital results and 1-year outcomes of transcatheter aortic valve-in-valve procedures and transcatheter aortic valve implantations in the native valves: the results from the Swiss-TAVI Registry. European Journal of Cardio-thoracic Surgery, 2019, 56, 55-63.	1.4	32
43	Five-year clinical outcomes and intracoronary imaging findings of the COMFORTABLE AMI trial: randomized comparison of biodegradable polymer-based biolimus-eluting stents with bare-metal stents in patients with acute ST-segment elevation myocardial infarction. European Heart Journal, 2019. 40. 1909-1919.	2.2	32
44	Clinical Outcomes According to Diabetic Status in Patients Treated With Biodegradable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents. Circulation: Cardiovascular Interventions, 2015, 8, .	3.9	29
45	Orsiro cobalt-chromium sirolimus-eluting stent: present and future perspectives. Expert Review of Medical Devices, 2017, 14, 773-788.	2.8	29
46	Age-Related Outcomes After Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2021, 14, 952-960.	2.9	28
47	Comparison of biolimus eluted from an erodible stent coating with bare metal stents in acute ST-elevation myocardial infarction (COMFORTABLE AMI trial): rationale and design. EuroIntervention, 2012, 7, 1435-1443.	3.2	27
48	Impact of the COVID-19 pandemic on acute coronary syndromes. Swiss Medical Weekly, 2020, 150, w20448.	1.6	27
49	European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1—epidemiology, pathophysiology, and diagnosis. Cardiovascular Research, 2022, 118, 1385-1412.	3.8	27
50	Should the 1h algorithm for rule in and rule out of acute myocardial infarction be used universally?Sometimes earlier may not be betterBackground, fundamental concepts, and scientific evidence of the high-sensitivity cardiac troponin 0h/1h-algorithm for early rule-out or rule-in of acute myocardial infarction. European Heart Journal, 2016, 37, 3316-3323.	2.2	26
51	Repositionable Versus Balloonâ€Expandable Devices for Transcatheter Aortic Valve Implantation in Patients With Aortic Stenosis. Journal of the American Heart Association, 2016, 5, .	3.7	25
52	Integrating the results of the CULPRIT-SHOCK trial in the 2017 ESC ST-elevation myocardial infarction guidelines: viewpoint of the task force. European Heart Journal, 2018, 39, 4239-4242.	2.2	25
53	The MI SYNTAX score for risk stratification in patients undergoing primary percutaneous coronary intervention for treatment of acute myocardial infarction: A substudy of the COMFORTABLE AMI trial. International Journal of Cardiology, 2014, 175, 314-322.	1.7	24
54	The peak of blood lactate during the first 24h predicts mortality in acute coronary syndrome patients under extracorporeal membrane oxygenation. International Journal of Cardiology, 2016, 221, 741-745.	1.7	24

#	Article	IF	CITATIONS
55	Gender differences in the decrease of in-hospital mortality in patients with acute myocardial infarction during the last 20 years in Switzerland. Open Heart, 2017, 4, e000689.	2.3	24
56	Long-Term Effect of Ultrathin-Strut Versus Thin-Strut Drug-Eluting Stents in Patients With Small Vessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2019, 12, e008024.	3.9	21
57	Gender-related mortality trends among diabetic patients with ST-segment elevation myocardial infarction: insights from a nationwide registry 1997–2010. European Heart Journal: Acute Cardiovascular Care, 2013, 2, 342-349.	1.0	19
58	Questions and answers on coronary revascularization: a companion document of the 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal, 2016, 37, e8-e14.	2.2	18
59	Interdisciplinary management of acute ischaemic stroke: Current evidence training requirements for endovascular stroke treatment: Position Paper from the ESC Council on Stroke and the European Association for Percutaneous Cardiovascular Interventions with the support of the European Board of Neurointervention, European Heart Journal, 2021, 42, 298-307.	2.2	18
60	Thyrotoxicosis and the cardiovascular system: subtle but serious effects Cleveland Clinic Journal of Medicine, 2003, 70, 57-63.	1.3	18
61	Treatment–risk paradox in acute coronary syndromes. European Heart Journal, 2018, 39, 3807-3809.	2.2	17
62	Fiveâ€Year Outcomes in Patients With Diabetes Mellitus Treated With Biodegradable Polymer Sirolimusâ€Eluting Stents Versus Durable Polymer Everolimusâ€Eluting Stents. Journal of the American Heart Association, 2019, 8, e013607.	3.7	17
63	Current role of emboli protection devices in percutaneous coronary and vascular interventions. American Heart Journal, 2009, 157, 263-270.	2.7	16
64	Diabetes and acute coronary syndromes. Best Practice and Research in Clinical Endocrinology and Metabolism, 2009, 23, 305-316.	4.7	16
65	Randomized comparison of biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for percutaneous coronary revascularization: Rationale and design of the BIOSCIENCE trial. American Heart Journal, 2014, 168, 256-261.	2.7	16
66	A Randomized Study of SheathLess vs Standard Guiding Catheters for Transradial Percutaneous Coronary Interventions. Canadian Journal of Cardiology, 2016, 32, 1425-1432.	1.7	16
67	Management of Combined Severe Carotid and Coronary Artery Disease. Current Cardiology Reports, 2012, 14, 125-134.	2.9	15
68	Management of vascular complications following transcatheter aortic valve implantation. Archives of Cardiovascular Diseases, 2015, 108, 491-501.	1.6	15
69	Quantitative Flow Ratio to Predict Nontarget Vessel–Related Events at 5 Years in Patients With ST‧egment–Elevation Myocardial Infarction Undergoing Angiographyâ€Guided Revascularization. Journal of the American Heart Association, 2021, 10, e019052.	3.7	15
70	Management of Patients With Concomitant Severe Coronary and Carotid Artery Disease. Circulation, 2007, 116, 2002-2004.	1.6	14
71	GuÃa de práctica clÃnÃca de la ESC sobre diagnóstico y tratamiento de las enfermedades arteriales periféricas. Revista Espanola De Cardiologia, 2012, 65, 172.e1-172.e57. 	1.2	14
72	Delayed manifestation of COVID-19 presenting as lower extremity multilevel arterial thrombosis: a case report. European Heart Journal - Case Reports, 2020, 4, 1-4.	0.6	14

#	Article	IF	CITATIONS
73	Meta-Analysis of Randomized Trials of Postconditioning in ST-Elevation Myocardial Infarction. American Journal of Cardiology, 2014, 114, 946-952.	1.6	13
74	Early Discharge in Low-Risk Patients Hospitalized for Acute Coronary Syndromes: Feasibility, Safety and Reasons for Prolonged Length of Stay. PLoS ONE, 2016, 11, e0161493.	2.5	13
75	Conduction disorders using the Evolut R prosthesis compared with the CoreValve: has anything changed?. Open Heart, 2018, 5, e000770.	2.3	12
76	A Critical Comparison of Canadian and International Guidelines Recommendations for Antiplatelet Therapy in Coronary Artery Disease. Canadian Journal of Cardiology, 2020, 36, 1298-1307.	1.7	12
77	Platelet Function Test Use for Patients with Coronary Artery Disease in the Early 2020s. Journal of Clinical Medicine, 2020, 9, 194.	2.4	12
78	Differential Effects of Newer-Generation Ultrathin-Strut Versus Thicker-Strut Drug-Eluting Stents in Chronic and AcuteÂCoronary Syndromes. JACC: Cardiovascular Interventions, 2021, 14, 2461-2473.	2.9	12
79	Incidence, Predictors, and Clinical Impact of Early Prasugrel Cessation in Patients With STâ€Elevation Myocardial Infarction. Journal of the American Heart Association, 2018, 7, .	3.7	11
80	Influence of intravenous fentanyl compared with morphine on ticagrelor absorption and platelet inhibition in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the PERSEUS randomized trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2019, 5, 158-163.	3.0	11
81	Impact of Patient and Lesion Complexity on Long-Term Outcomes Following Coronary Revascularization With New-Generation Drug-Eluting Stents. American Journal of Cardiology, 2017, 119, 501-507.	1.6	10
82	Routine beta-blocker administration following acute myocardial infarction: why still an unsolved issue?. Journal of Thoracic Disease, 2017, 9, 4191-4194.	1.4	10
83	New-onset or Pre-existing Atrial Fibrillation in Acute Coronary Syndromes: Two Distinct Phenomena With a Similar Prognosis. Revista Espanola De Cardiologia (English Ed), 2019, 72, 383-391.	0.6	10
84	Symptomatic Carotid Artery Disease: Revascularization. Progress in Cardiovascular Diseases, 2017, 59, 601-611.	3.1	9
85	Outcomes and regional differences in practice in a worldwide coronary stent registry. Heart, 2022, 108, 1310-1318.	2.9	9
86	Management of Patients with Carotid Artery Stenosis. Herz, 2008, 33, 490-497.	1.1	8
87	Current evidence for carotid endarterectomy and carotid artery stenting. Heart, 2010, 96, 636-642.	2.9	8
88	Circadian dependence of manual thrombus aspiration benefit in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Clinical Research in Cardiology, 2018, 107, 338-346.	3.3	8
89	Percutaneous Coronary Intervention of Chronic Total Occlusions in Patients with Diabetes Mellitus: a Treatment-Risk Paradox. Current Cardiology Reports, 2019, 21, 9.	2.9	8
90	Is there a role for revascularisation in asymptomatic carotid stenosis? Yes. BMJ: British Medical Journal, 2010, 341, c4898-c4898.	2.3	8

Marco Roffi

#	Article	IF	CITATIONS
91	Thirty-day Outcome Following CoreValve Evolut R Transcatheter Aortic Valve Implantation: An All-comers Prospective Study. Revista Espanola De Cardiologia (English Ed), 2017, 70, 713-719.	0.6	7
92	CTO PCI in Patients With Diabetes Mellitus. JACC: Cardiovascular Interventions, 2017, 10, 2182-2184.	2.9	7
93	Prognostic values of fasting hyperglycaemia in non-diabetic patients with acute coronary syndrome: A prospective cohort study. European Heart Journal: Acute Cardiovascular Care, 2020, 9, 589-598.	1.0	7
94	Overcoming the Challenges of the Transfemoral Approach in Transcatheter Aortic Valve Implantation. Interventional Cardiology Review, 2013, 8, 131.	1.6	7
95	Safety of Prasugrel Loading Doses inÂPatients Pre-Loaded With ClopidogrelÂinÂtheÂSetting of Primary Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2015, 8, 1064-1074.	2.9	6
96	Coronavirus disease 2019-associated coronary endotheliitis and thrombotic microangiopathy causing cardiogenic shock: a case report. European Heart Journal - Case Reports, 2022, 6, ytac061.	0.6	6
97	Starting a carotid artery stenting program is safe. Catheterization and Cardiovascular Interventions, 2008, 71, 469-473.	1.7	5
98	Carotid artery stenting. Heart, 2016, 102, 1059-1069.	2.9	5
99	Minimizing Distal Embolization DuringÂCarotid Artery Stenting. JACC: Cardiovascular Interventions, 2019, 12, 404-405.	2.9	5
100	Multisite vascular disease in acute coronary syndromes: increased in-hospital mortality and no improvement over time. European Heart Journal: Acute Cardiovascular Care, 2020, 9, 748-757.	1.0	5
101	Temporal trends in cardiovascular risk factors' prevalence in patients with myocardial infarction. European Journal of Clinical Investigation, 2021, 51, e13466.	3.4	5
102	Five-Year Outcomes With Biodegradable-Polymer Sirolimus-Eluting Stents Versus Durable-Polymer Everolimus-Eluting Stents in Patients With Acute Coronary Syndrome: A Subgroup Analysis of the BIOSCIENCE Trial. Cardiovascular Revascularization Medicine, 2022, 34, 3-10.	0.8	5
103	Clinical Perspectives and Pearls from the 2015 ESC NSTE-ACS Guidelines. Current Cardiology Reports, 2016, 18, 48.	2.9	4
104	Impact of total ischemic time on manual thrombus aspiration benefit during primary percutaneous coronary intervention. American Heart Journal, 2018, 204, 34-42.	2.7	4
105	Report of the European Society of Cardiology Cardiovascular Round Table regulatory workshop update of the evaluation of new agents for the treatment of acute coronary syndrome: Executive summary. European Heart Journal: Acute Cardiovascular Care, 2019, 8, 745-754.	1.0	4
106	Young woman with cardiac arrest due to spontaneous coronary artery dissection. Anatolian Journal of Cardiology, 2019, 23, 53-55.	0.9	4
107	Current perspectives on coronary revascularization in the diabetic patient. Indian Heart Journal, 2007, 59, 124-36.	0.5	4
108	Platelet glycoprotein IIb/IIIa receptor inhibitorsend of an era?. European Heart Journal, 2008, 29, 429-431.	2.2	3

#	Article	IF	CITATIONS
109	Cryptogenic stroke with right-to-left shunt and no patent foramen ovale. Archives of Cardiovascular Diseases, 2014, 107, 418-419.	1.6	3
110	The struggle of carotid artery stenting. Lancet, The, 2015, 385, 490-491.	13.7	3
111	Percutaneous PFO closure for cryptogenic stroke in the setting of a systematic cardiac and neurological screening and a standardised follow-up protocol. Open Heart, 2017, 4, e000475.	2.3	3
112	How should I treat a complex left subclavian artery stenosis involving the vertebral artery in a patient with subclavian steal syndrome and left internal mammary artery bypass graft?. EuroIntervention, 2015, 10, e1-e7.	3.2	3
113	Questions and answers on antithrombotic therapy: a companion document of the 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal, 2016, 37, e1-e7.	2.2	2
114	Impact of angiographic coronary artery disease complexity on ischemic and bleeding risks and on the comparative effectiveness of zotarolimus-eluting vs. bare-metal stents in uncertain drug-eluting stent candidates. International Journal of Cardiology, 2019, 277, 60-65.	1.7	2
115	Heavy Drinking Habits Are Associated with Worse In-Hospital Outcomes in Patients with Acute Coronary Syndrome: An Insight from the AMIS Plus Registry. Cardiology, 2020, 145, 757-765.	1.4	2
116	Embolization to Two Different Vascular Territories in a Patient With Bicuspid Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation. CJC Open, 2020, 2, 432-434.	1.5	2
117	What is new in the 2020 ESC NSTEâ€ACS guidelines. European Journal of Clinical Investigation, 2021, 51, e13422.	3.4	2
118	Multivessel percutaneous coronary intervention with thin-strut biodegradable versus durable polymer drug-eluting stents in ST-segment elevation myocardial infarction: A subgroup analysis of the BIOSTEMI randomized trial. International Journal of Cardiology, 2021, 334, 37-41.	1.7	2
119	Digital transformation of major scientific meetings induced by the COVID-19 pandemic: insights from the ESC 2020 annual congress. European Heart Journal Digital Health, 2021, 2, 704-712.	1.7	2
120	Exclusion of a coronary aneurysm with a polyurethane covered stent. Turk Kardiyoloji Dernegi Arsivi, 2019, 47, 609-611.	0.5	2
121	Determinants of hospital length of stay after transcatheter aortic valve implantation with self-expanding prostheses: a prospective, single centre observational study. Swiss Medical Weekly, 2019, 149, w20095.	1.6	2
122	Percutaneous intervention of saphenous vein grafts. ACC Current Journal Review, 2004, 13, 45-48.	0.1	1
123	Pre-hospital alarm activation for STEMI patients undergoing primary percutaneous coronary intervention in the era of transradial procedures. European Journal of Internal Medicine, 2016, 35, 83-88.	2.2	1
124	Newer Generation Drug-Eluting StentsÂforÂRevascularization of ChronicÂTotal Occlusions. JACC: Cardiovascular Interventions, 2017, 10, 144-146.	2.9	1
125	A giant coronary artery aneurysm associated with multiple peripheral arterial aneurysms and an abdominal aortic aneurysm. European Journal of Cardio-thoracic Surgery, 2018, 54, 598-600.	1.4	1
126	Percutaneous coronary intervention under temporary peripheral veno-arterial extracorporeal membrane oxygenation. European Heart Journal: Acute Cardiovascular Care, 2020, 9, NP3-NP5.	1.0	1

#	Article	IF	CITATIONS
127	Successful percutaneous mechanical thrombectomy of an Impella CP-related femoral artery thrombosis. Cardiology Journal, 2021, 28, 185-186.	1.2	1
128	Intravascular lithotripsy to treat an ostial left main coronary artery stenosis due to porcelain aorta in a patient with congenital HDL deficiency. Anatolian Journal of Cardiology, 2020, 24, 345-346.	0.9	1
129	Unexpected Interrupted Inferior Vena Cava Diagnosed During Failed Transcatheter Left Atrial Appendage Closure. Revista Espanola De Cardiologia (English Ed), 2016, 69, 704-706.	0.6	0
130	Recurrent Vasospastic Myocardial Infarctions and Hand Necrosis. JACC: Cardiovascular Interventions, 2017, 10, 198-199.	2.9	0
131	Letter by Mueller and Roffi Regarding Article, "Assessment of the European Society of Cardiology 0-Hour/1-Hour Algorithm to Rule-Out and Rule-In Acute Myocardial Infarction― Circulation, 2017, 135, e921-e922.	1.6	0
132	Medically–managed Patients With Non ST-segment Elevation Acute Coronary Syndromes: An Ill-defined Entity. Revista Espanola De Cardiologia (English Ed), 2017, 70, 796-798.	0.6	0
133	Tratamiento conservador en pacientes con sÃndrome coronario agudo sin elevación del ST: unaÂentidad mal definida. Revista Espanola De Cardiologia, 2017, 70, 796-798.	1.2	0
134	Commentary: The Long and Winding Road. Journal of Endovascular Therapy, 2018, 25, 608-610.	1.5	0
135	What a Congress!. European Heart Journal, 2019, 40, 3507-3509.	2.2	0
136	ESC CONGRESS 2020—the digital experience: expanding the reach of the society. European Heart Journal, 2021, 42, 2812-2813.	2.2	0
137	Percutaneous Coronary Interventions for NSTEMI and Unstable Angina. , 2018, , 245-253.		0
138	Recurrent myocardial infarction caused by peripartum left main spontaneous coronary artery dissection, extending to the left anterior descending artery and left circumflex artery. Cardiology Journal, 2020, 27, 206-207.	1.2	0
139	Author`s Reply. Anatolian Journal of Cardiology, 2020, 23, 242.	0.9	0
140	Author`s Reply. Anatolian Journal of Cardiology, 2020, 23, 240-241.	0.9	0